Navigation Links
Broader organ sharing won't harm liver transplant recipients

New research shows that broader sharing of deceased donor livers will not significantly increase cold ischemia time (CIT)the time the liver is in a cooled state outside the donor suggesting that this is not a barrier to broader sharing of organs. However, findings published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, do indicate that broader sharing of organs will significantly increase the percentage of donor organs that are transported by flying rather than driving.

The ongoing shortage of livers available for transplantation continues to be a concern in the U.S., impacting some geographic areas more than others. Recent allocation policy changes seek to address organ shortages and reduce geographic disparity. Livers are offered at the regional level first to candidates most at risk of death (status 1) and those with Model for End-Stage Liver Disease (MELD) a score of 35 or more before being offered to local wait list candidates.

"Shortages and geographic inequity of organs available for transplant have required the liver transplant community to reassess the allocation policy in the U.S., and even broader sharing of organs may be needed," explains Dr. Sommer Gentry with the United States Naval Academy in Annapolis, Md. "One concern with broader sharing is that transport times may increase and affect CIT, which could impair organ quality."

For the present study, the team first surveyed all organ procurement organizations to verify use of helicopters for transporting liver allografts, if a central facility was used to recover the organ, and at what distance the mode of transportation changed from driving to flying. Using the Scientific Registry of Transplant Recipients, researchers identified 111 centers that performed at least one adult liver transplant along with hospitals that recovered at least one of the 1284 deceased donor livers recovered in 2010. There were 809 public, private, and military owned airports used for organ transports.

A detailed model of driving, helicopter, or airplane and transport times between all hospitals was constructed. Results show that the median transport time estimated for regionally shared livers was two hours compared to 1 hour for livers used within the local area. The model-predicted transport mode was flying for 90% of livers shared at the regional level and 22% for locally allocated organs.

The median CIT was seven hours for livers shared regionally versus six hours for those used in the local area. Transport time comprised about 21% of CIT and variation in transport time accounted for roughly 15% of CIT variation. "Our findings indicate that non-transport factors impact CIT much more than transport time," concludes Dr. Gentry. "Broader sharing of livers will not have much effect on CIT or negatively impact the liver transplant recipient, but will significantly increase the number of organs transported by flying."


Contact: Dawn Peters

Related medicine news :

1. UofL researcher and team explore broader definition of successful aging
2. Commonly used intra-aortic balloon pump may have broader potential for heart patients
3. Targets of anticancer drugs have broader functions than what their name suggests
4. Study Supports Broader Access to Lap-Band Weight-Loss Surgery
5. Broader background checks and denial criteria could help prevent mass shooting catastrophes
6. Texas Organizations Pull Together to Protect Families from Hereditary Cancers
7. ATCC Adds ISO 13485:2003 Certification to Its Quality Management Program to Further Strengthen the Organization’s Commitment to the Production of Quality Products
8. SML Taps Organizational Guru For First, Live Facebook Interview
9. Asbestos Disease Awareness Organization Declares Briefing with Senate Staff Members a Success, Baron and Budd Reports
10. Surveys Reveal the Top 10 Organic Cotton Users and the Top 10 Producing Countries
11. Two Moms in the Raw Launches Three New, Raw, Sprouted 100% Organic Snacks
Post Your Comments:
Related Image:
Broader organ sharing won't harm liver transplant recipients
(Date:12/1/2015)... ... December 01, 2015 , ... ... 7th Annual 2015 Golden Bridge Business Awards under the New Products and Services ... capex web based sample management software that helps labs organize data ...
(Date:12/1/2015)... ... 01, 2015 , ... For many X-rays taken at hospitals, ... interpretation by the radiologist. The marking utensils are so small, however, they are ... a way to alleviate this problem. , He developed the patent-pending MARK N ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, ... been awarded a fixed price per sprint agile development contract to support the ... million over five years, provides software engineering, infrastructure, as well as operations and ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech North ... Gary has spent a significant amount of time in Sweden since joining PartnerTech ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani ... Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled ... Contact Center solutions targeted to the high-end enterprise contact center marketplace. , Ed ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a country ... drugs registered in Europe in 2015 were tested ... Russia has always been a country of choice ...
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: